10-Q: Oramed Pharmaceuticals Reports Strong Financial Income

Oramed Pharmaceuticals Inc. filed its Form 10-Q for the period ended June 30, 2026, reporting substantial financial income driven by investment revaluations, alongside an operating loss.

Summary

• Oramed Pharmaceuticals Inc. reported a net income of $116.5 million for the six months ended June 30, 2026, a significant increase from $5.6 million in the same period last year. This was largely driven by financial income of $148.6 million, primarily from the revaluation of investments, particularly in Alpha Tau.
• The company experienced an operating loss of $6.4 million for the six months ended June 30, 2026, compared to a loss of $7.0 million in the prior year period. This was due to increased general and administrative expenses, partially offset by reduced research and development expenses.
• As of June 30, 2026, Oramed had $15.2 million in cash and cash equivalents, with total assets of $369.6 million and total liabilities of $41.4 million, resulting in total stockholders' equity of $317.5 million.
• The company completed the Lifeward transaction on March 25, 2026, transferring its POD technology platform to OraTech in exchange for Lifeward shares, warrants, and revenue-sharing payments.
• Oramed continues to manage a diverse portfolio of investments, including significant stakes in Alpha Tau and Lifeward, and has entered into new loan agreements and participation interests in real estate projects.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to significant financial income from investment revaluations, despite an operating loss. The company's strategic shift and diverse investments indicate potential for future value creation.

Positives

• Significant increase in net income to $116.5 million for the six months ended June 30, 2026, up from $5.6 million in the prior year.
• Substantial financial income of $148.6 million for the six months ended June 30, 2026, primarily from investment revaluations, notably in Alpha Tau.
• Positive working capital surplus of $42.7 million as of June 30, 2026.
• Successful completion of the Lifeward transaction, diversifying Oramed's holdings and providing near-term cash flow.
• Strategic investments in Alpha Tau and Lifeward, which are considered high-potential innovation areas.
• The company's cash and cash equivalents stood at $15.2 million as of June 30, 2026, providing liquidity for planned activities.
• The company has no further obligations to the Israel Innovation Authority (IIA).

Negatives

• Operating loss of $6.4 million for the six months ended June 30, 2026.
• Increase in general and administrative expenses by 28% for the six months ended June 30, 2026, driven by stock-based compensation and professional fees.
• Cash and cash equivalents decreased to $15.2 million from $45.9 million at the end of the previous year.
• The company has incurred cumulative losses of approximately $7.0 million since inception through June 30, 2026.
• Deferred tax liabilities increased significantly to $39.5 million from $7.9 million.

Risks

• The company may not be able to secure additional financing on acceptable terms, which could force it to reduce operations or divest assets.
• Fluctuating market prices and liquidity of common stock of Scilex, Alpha Tau, and Lifeward, which underlie warrants held by Oramed.
• Loan agreements in real estate projects expose Oramed to potential market, liquidity, and execution risks.
• Real estate investments may not provide long-term value appreciation or expected income streams.
• Exposure to potential litigation.
• Foreign currency exchange rate fluctuations, primarily related to the Israeli New Shekel, may affect operating expenses and financial results.
• Risks related to investments in private equity funds, including illiquidity, capital call obligations, and potential loss of invested capital.

Future Outlook

Oramed is transforming into a strategic healthcare operating company focused on building long-term value through active ownership and operational leadership, selectively acquiring strategic positions in companies where it can leverage its expertise. The company expects to continue managing its portfolio of holdings and may seek additional financing.

Management Comments

• Oramed has transformed into a strategic healthcare operating company focused on building long-term value through active ownership and operational leadership.
• We selectively acquire meaningful strategic positions in companies where we can leverage our expertise across corporate strategy, clinical and regulatory development, commercialization, capital markets, and business growth.
• By partnering closely with management and providing hands-on operational guidance, we seek to accelerate innovation and unlock the full potential of our portfolio companies.
• Our value creation is driven by operating and growing these businesses, with a focus on long-term strategic development and real-world impact.

Industry Context

StockSavvy.ai notes that Oramed's strategic shift towards an operating company model, focusing on active ownership and leveraging expertise in healthcare investments, aligns with broader trends in the venture capital and private equity sectors within the life sciences industry. The company's diversified investment portfolio, including stakes in publicly traded biotech firms like Alpha Tau and Lifeward, reflects a strategy to generate value through both operational improvements and market appreciation of its holdings.

Comparison to Industry Standards

• Oramed's reported net income of $116.5 million for the six months ended June 30, 2026, driven by financial income from investment revaluations, is a notable outlier compared to many early-stage biotech companies that typically report operating losses and negative net income.
• The company's strategy of investing in and actively managing stakes in other healthcare companies, such as Alpha Tau and Lifeward, is a common approach for diversified healthcare investment firms, but Oramed's specific focus on leveraging its own expertise in clinical and regulatory development is a key differentiator.
• The significant increase in financial income, largely from the revaluation of Alpha Tau shares, highlights the volatility and potential for high returns (and losses) associated with investments in publicly traded biotechnology companies, a characteristic common across the sector.

Legal Proceedings

• From time to time, the company may become involved in legal proceedings or be subject to claims arising in the ordinary course of business.

Related Party Transactions

• Consulting agreement with KNRY Ltd. (owned by Chief Scientific Officer) for services as Chief Scientific Officer.
• Employment agreement with the Chief Scientific Officer.
• Consulting agreement with Shnida Ltd. (owned by President and Chief Executive Officer) for services as President and Chief Executive Officer.
• Employment agreement with the President and Chief Executive Officer.
• Clinical Trial Management Agreement with OraTech, where Oramed manages clinical studies for OraTech's investigational oral insulin capsule product.

Stakeholder Impact

• Shareholders may benefit from the potential value creation through active management of the investment portfolio and the strategic shift towards an operating company model.
• Employees may be impacted by the company's strategic direction and investment activities.
• Creditors and suppliers are likely to be impacted by the company's financial performance and liquidity, which is supported by current cash resources and a positive working capital surplus.

Next Steps

• Continue to actively manage its portfolio of holdings in publicly traded and privately held companies.
• Evaluate potential strategic opportunities, including expanding into additional therapeutic and technology areas, and acquiring or investing in additional businesses or assets.
• Manage the clinical development program for the refined oral insulin program.
• Monitor and potentially exercise rights related to the Lifeward Notes Purchase Agreement, including the potential funding of a second tranche of notes.
• Continue to manage investments in Alpha Tau and Lifeward, and other portfolio companies.

Key Dates

Recommendation

Oramed's strategic shift and significant financial income from investments are positive, but the continued operating loss and reliance on investment revaluations warrant a cautious approach. The company's ability to execute its new strategy and manage its diverse portfolio will be key. A 'hold' recommendation reflects the balance between potential upside from strategic investments and the ongoing operational challenges.

Keywords

Oramed Pharmaceuticals, Form 10-Q, Financial Statements, Investment Revaluation, Alpha Tau, Lifeward, Scilex, Operating Loss